Radiosensitizing potential of epigenetic anticancer drugs

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 1, 2009, Pages 99-108

  De Schutter, Harlinde ^a   Nuyts, Sandra ^a  

^a Katholieke Universiteit   (Belgium)

Author keywords

Anticancer drugs; Demethylating agents; Epigenetic; Histone deacetylase inhibitors; Radiosensitization; Radiotherapy

Indexed keywords

4 CARBOXYCINNAMIC ACID BISHYDROXAMIDE; 4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BUTYRIC ACID; CINNAMIC ACID; COMPLEMENTARY RNA; CYTIDINE; DEOXYCYTIDINE; DEPSIPEPTIDE; DNA METHYLTRANSFERASE 1; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; NUCLEOSIDE DERIVATIVE; PANOBINOSTAT; PCI 24781; PHENYLACETIC ACID; PROCAINAMIDE; PROCAINE; ROMIDEPSIN; SK 7041; SMALL INTERFERING RNA; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE; ANTINEOPLASTIC AGENT; RADIOSENSITIZING AGENT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW TOXICITY; CANCER INVASION; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; DRUG MEGADOSE; ENZYME INHIBITION; EPIGENETICS; EXTERNAL BEAM RADIOTHERAPY; GENE SILENCING; HEMATOLOGIC MALIGNANCY; HUMAN; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; RADIOSENSITIZATION; REVIEW; SOLID TUMOR; TRANSCRIPTION INITIATION; TUMOR IMMUNITY; DRUG ANTAGONISM; DRUG EFFECT; GENETIC EPIGENESIS; MULTIMODALITY CANCER THERAPY; NEOPLASM;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HUMANS; NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 61749098365     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009787047707     Document Type: Review

References (104)

1. Baylin, S. B.; Ohm, J. E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer, 2006, 6, 107-116.
2. Esteller, M. The necessity of a human epigenome project. Carcinogenesis, 2006, 27, 1121-1125.
3. Esteller, M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br. J. Cancer, 2006, 94, 179-183.
4. Baylin, S. B. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol., 2005, 2 Suppl 1, S4-11.
5. Gore, S. D.; Baylin, S.; Sugar, E.; Carraway, H.; Miller, C. B.; Carducci, M.; Grever, M.; Galm, O.; Dauses, T.; Karp, J. E.; Rudek, M. A.; Zhao, M.; Smith, B. D.; Manning, J.; Jiemjit, A.; Dover, G.; Mays, A.; Zwiebel, J.; Murgo, A.; Weng, L. J.; Herman, J. G. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res., 2006, 66, 6361-6369.
6. Issa, J. P.; Garcia-Manero, G.; Giles, F. J.; Mannari, R.; Thomas, D.; Faderl, S.; Bayar, E.; Lyons, J.; Rosenfeld, C. S.; Cortes, J.; Kantarjian, H. M. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood, 2004, 103, 1635-1640.
7. Kantarjian, H.; Oki, Y.; Garcia-Manero, G.; Huang, X.; O'Brien, S.; Cortes, J.; Faderl, S.; Bueso-Ramos, C.; Ravandi, F.; Estrov, Z.; Ferrajoli, A.; Wierda, W.; Shan, J.; Davis, J.; Giles, F.; Saba, H. I.; Issa, J. P. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 2007, 109, 52-57.
8. Mund, C.; Hackanson, B.; Stresemann, C.; Lubbert, M.; Lyko, F. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res., 2005, 65, 7086-7090.
9. Abele, R.; Clavel, M.; Dodion, P.; Bruntsch, U.; Gundersen, S.; Smyth, J.; Renard, J.; van, G. M.; Pinedo, H. M. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur. J. Cancer Clin. Oncol., 1987, 23, 1921-1924.
10. Gollob, J. A.; Sciambi, C. J.; Peterson, B. L.; Richmond, T.; Thoreson, M.; Moran, K.; Dressman, H. K.; Jelinek, J.; Issa, J. P. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin. Cancer Res., 2006, 12, 4619-4627.
11. Marquez, V. E.; Kelley, J. A.; Agbaria, R.; Ben-Kasus, T.; Cheng, J. C.; Yoo, C. B.; Jones, P. A. Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. Ann. N. Y. Acad. Sci., 2005, 1058, 246-254.
12. Lyko, F.; Brown, R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J. Natl. Cancer Inst., 2005, 97, 1498-1506.
13. Karpf, A. R.; Jones, D. A. Reactivating the expression of methylation silenced genes in human cancer. Oncogene, 2002, 21, 5496-5503.
14. Liang, G.; Gonzales, F. A.; Jones, P. A.; Orntoft, T. F.; Thykjaer, T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res., 2002, 62, 961-966.
15. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov., 2006, 5, 769-784.
16. Karagiannis, T. C.; El-Osta, A. Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene, 2006, 25, 3885-3893.
17. Karagiannis, T. C.; El-Osta, A. Clinical potential of histone deacetylase inhibitors as stand alone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer. Epigenetics, 2006, 1, 121-126.
18. Kouraklis, G.; Theocharis, S. Histone deacetylase inhibitors: a novel target of anticancer therapy (review). Oncol. Rep., 2006, 15, 489-494.
19. Park, J. H.; Jung, Y.; Kim, T. Y.; Kim, S. G.; Jong, H. S.; Lee, J. W.; Kim, D. K.; Lee, J. S.; Kim, N. K.; Kim, T. Y.; Bang, Y. J. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res., 2004, 10, 5271-5281.
20. Balasubramanian, S.; Ramos, J.; Luo, W.; Sirisawad, M.; Verner, E.; Buggy, J. J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia, 2008, 22, 1026-1034.
21. Dokmanovic, M.; Marks, P. A. Prospects: histone deacetylase inhibitors. J. Cell. Biochem., 2005, 96, 293-304.
22. Carew, J. S.; Giles, F. J.; Nawrocki, S. T. Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy. Cancer Lett., 2008, 269, 7-17.
23. Chen, J. S.; Faller, D. V. Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts. J. Cell Physiol., 2005, 202, 87-99.
24. Marks, P. A.; Richon, V. M.; Breslow, R.; Rifkind, R. A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol., 2001, 13, 477-483.
25. Deroanne, C. F.; Bonjean, K.; Servotte, S.; Devy, L.; Colige, A.; Clausse, N.; Blacher, S.; Verdin, E.; Foidart, J. M.; Nusgens, B. V.; Castronovo, V. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene, 2002, 21, 427-436.
26. Goh, M.; Chen, F.; Paulsen, M. T.; Yeager, A. M.; Dyer, E. S.; Ljungman, M. Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells. Neoplasia, 2001, 3, 331-338.
27. Crazzolara, R.; Johrer, K.; Johnstone, R. W.; Greil, R.; Kofler, R.; Meister, B.; Bernhard, D. Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. Br. J. Haematol., 2002, 119, 965-969.
28. Qian, D. Z.; Kato, Y.; Shabbeer, S.; Wei, Y.; Verheul, H. M.; Salumbides, B.; Sanni, T.; Atadja, P.; Pili, R. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res., 2006, 12, 634-642.
29. Liu, L. T.; Chang, H. C.; Chiang, L. C.; Hung, W. C. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res., 2003, 63, 3069-3072.
30. Pulukuri, S. M.; Gorantla, B.; Rao, J. S. Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator. J. Biol. Chem., 2007, 282, 35594-35603.
31. Nencioni, A.; Beck, J.; Werth, D.; Grunebach, F.; Patrone, F.; Ballestrero, A.; Brossart, P. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin. Cancer Res., 2007, 13, 3933-3941.
32. Tao, R.; de Zoeten, E. F.; Ozkaynak, E.; Chen, C.; Wang, L.; Porrett, P. M.; Li, B.; Turka, L. A.; Olson, E. N.; Greene, M. I.; Wells, A. D.; Hancock, W. W. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med., 2007, 13, 1299-1307.
33. Martinez-Balbas, M. A.; Bauer, U. M.; Nielsen, S. J.; Brehm, A.; Kouzarides, T. Regulation of E2F1 activity by acetylation. EMBO J., 2000, 19, 662-671.
34. Nusinzon, I.; Horvath, C. M. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 14742-14747.
35. Yuan, Z. L.; Guan, Y. J.; Chatterjee, D.; Chin, Y. E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science, 2005, 307, 269-273.
36. Chen, L.; Fischle, W.; Verdin, E.; Greene, W. C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science, 2001, 293, 1653-1657.
37. Siddiqui, H.; Solomon, D. A.; Gunawardena, R. W.; Wang, Y.; Knudsen, E. S. Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition. Mol. Cell Biol., 2003, 23, 7719-7731.
38. Gu, W.; Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell, 1997, 90, 595-606.
39. Scroggins, B. T.; Robzyk, K.; Wang, D.; Marcu, M. G.; Tsutsumi, S.; Beebe, K.; Cotter, R. J.; Felts, S.; Toft, D.; Karnitz, L.; Rosen, N.; Neckers, L. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell, 2007, 25, 151-159.
40. Subramanian, C.; Opipari, A. W., Jr.; Bian, X.; Castle, V. P.; Kwok, R. P. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 4842-4847.
41. Munshi, A.; Kurland, J. F.; Nishikawa, T.; Tanaka, T.; Hobbs, M. L.; Tucker, S. L.; Ismail, S.; Stevens, C.; Meyn, R. E. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res., 2005, 11, 4912-4922.
42. Zhang, Y.; Carr, T.; Dimtchev, A.; Zaer, N.; Dritschilo, A.; Jung, M. Attenuated DNA damage repair by trichostatin A through BRCA1 suppression. Radiat. Res., 2007, 168, 115-124.
43. Chinnaiyan, P.; Vallabhaneni, G.; Armstrong, E.; Huang, S. M.; Harari, P. M. Modulation of radiation response by histone deacetylase inhibition. Int. J. Radiat. Oncol. Biol. Phys., 2005, 62, 223-229.
44. Kim, G. D.; Choi, Y. H.; Dimtchev, A.; Jeong, S. J.; Dritschilo, A.; Jung, M. Sensing of ionizing radiation-induced DNA damage by ATM through interaction with histone deacetylase. J. Biol. Chem., 1999, 274, 31127-31130.
45. Kao, G. D.; McKenna, W. G.; Guenther, M. G.; Muschel, R. J.; Lazar, M. A.; Yen, T. J. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. J. Cell Biol., 2003, 160, 1017-1027.
46. Ou, J. N.; Torrisani, J.; Unterberger, A.; Provencal, N.; Shikimi, K.; Karimi, M.; Ekstrom, T. J.; Szyf, M. Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem. Pharmacol., 2007, 73, 1297-1307.
47. Gius, D.; Cui, H.; Bradbury, C. M.; Cook, J.; Smart, D. K.; Zhao, S.; Young, L.; Brandenburg, S. A.; Hu, Y.; Bisht, K. S.; Ho, A. S.; Mattson, D.; Sun, L.; Munson, P. J.; Chuang, E. Y.; Mitchell, J. B.; Feinberg, A. P. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell, 2004, 6, 361-371.
48. Cameron, E. E.; Bachman, K. E.; Myohanen, S.; Herman, J. G.; Baylin, S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet., 1999, 21, 103-107.
49. Danbara, M.; Kameyama, K.; Higashihara, M.; Takagaki, Y. DNA methylation dominates transcriptional silencing of Pax5 in terminally differentiated B cell lines. Mol. Immunol., 2002, 38, 1161-1166.
50. Steiner, F. A.; Hong, J. A.; Fischette, M. R.; Beer, D. G.; Guo, Z. S.; Chen, G. A.; Weiser, T. S.; Kassis, E. S.; Nguyen, D. M.; Lee, S.; Trepel, J. B.; Schrump, D. S. Sequential 5-Aza 2'-deoxycytidine/ depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene, 2005, 24, 2386-2397.
51. Zhu, W. G.; Dai, Z.; Ding, H.; Srinivasan, K.; Hall, J.; Duan, W.; Villalona-Calero, M. A.; Plass, C.; Otterson, G. A. Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells. Oncogene, 2001, 20, 7787-7796.
52. Zhu, W. G.; Otterson, G. A. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr. Med. Chem. Anticancer Agents, 2003, 3, 187-199.
53. Yang, H.; Hoshino, K.; Sanchez-Gonzalez, B.; Kantarjian, H.; Garcia-Manero, G. Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk. Res., 2005, 29, 739-748.
54. Venturelli, S.; Armeanu, S.; Pathil, A.; Hsieh, C. J.; Weiss, T. S.; Vonthein, R.; Wehrmann, M.; Gregor, M.; Lauer, U. M.; Bitzer, M. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer, 2007, 109, 2132-2141.
55. Karam, J. A.; Fan, J.; Stanfield, J.; Richer, E.; Benaim, E. A.; Frenkel, E.; Antich, P.; Sagalowsky, A. I.; Mason, R. P.; Hsieh, J. T. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int. J. Cancer, 2007, 120, 1795-1802.
56. Walton, T. J.; Li, G.; Seth, R.; McArdle, S. E.; Bishop, M. C.; Rees, R. C. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate, 2008, 68, 210-222.
57. Hurtubise, A.; Momparler, R. L. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother. Pharmacol., 2006, 58, 618-625.
58. Garcia-Manero, G.; Kantarjian, H. M.; Sanchez-Gonzalez, B.; Yang, H.; Rosner, G.; Verstovsek, S.; Rytting, M.; Wierda, W. G.; Ravandi, F.; Koller, C.; Xiao, L.; Faderl, S.; Estrov, Z.; Cortes, J.; O'Brien, S.; Estey, E.; Bueso-Ramos, C.; Fiorentino, J.; Jabbour, E.; Issa, J. P. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood, 2006, 108, 3271-3279.
59. Kim, W. J.; Vo, Q. N.; Shrivastav, M.; Lataxes, T. A.; Brown, K. D. Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line. Oncogene, 2002, 21, 3864-3871.
60. Roy, K.; Wang, L.; Makrigiorgos, G. M.; Price, B. D. Methylation of the ATM promoter in glioma cells alters ionizing radiation sensitivity. Biochem. Biophys. Res. Commun., 2006, 344, 821-826.
61. Sakakura, C.; Miyagawa, K.; Fukuda, K. I.; Nakashima, S.; Yoshikawa, T.; Kin, S.; Nakase, Y.; Ida, H.; Yazumi, S.; Yamagishi, H.; Okanoue, T.; Chiba, T.; Ito, K.; Hagiwara, A.; Ito, Y. Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis. Oncogene, 2007, 26, 5927-5938.
62. Dote, H.; Cerna, D.; Burgan, W. E.; Carter, D. J.; Cerra, M. A.; Hollingshead, M. G.; Camphausen, K.; Tofilon, P. J. Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin. Cancer Res., 2005, 11, 4571-4579.
63. Nackerdien, Z.; Michie, J.; Bohm, L. Chromatin decondensed by acetylation shows an elevated radiation response. Radiat. Res., 1989, 117, 234-244.
64. Warters, R. L.; Childers, T. J. Radiation-induced thymine base damage in replicating chromatin. Radiat. Res., 1982, 90, 564-574.
65. Arundel, C. M.; Glicksman, A. S.; Leith, J. T. Enhancement of radiation injury in human colon tumor cells by the maturational agent sodium butyrate (NaB). Radiat. Res., 1985, 104, 443-448.
66. Arundel, C. M.; Leith, J. T. Effects of nucleoside analogs and sodium butyrate on recovery from potentially lethal X ray damage in human colon tumor cells. Int. J. Radiat. Oncol. Biol. Phys., 1987, 13, 593-601.
67. Leith, J. T. Effects of sodium butyrate and 3-aminobenzamide on survival of Chinese hamster HA-1 cells after X irradiation. Radiat. Res., 1988, 114, 186-191.
68. Biade, S.; Stobbe, C. C.; Boyd, J. T.; Chapman, J. D. Chemical agents that promote chromatin compaction radiosensitize tumour cells. Int. J. Radiat. Biol., 2001, 77, 1033-1042.
69. Flatmark, K.; Nome, R. V.; Folkvord, S.; Bratland, A.; Rasmussen, H.; Ellefsen, M. S.; Fodstad, O.; Ree, A. H. Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiat. Oncol., 2006, 1, 25.
70. Kim, I. A.; Shin, J. H.; Kim, I. H.; Kim, J. H.; Kim, J. S.; Wu, H. G.; Chie, E. K.; Ha, S. W.; Park, C. I.; Kao, G. D. Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. Clin. Cancer Res., 2006, 12, 940-949.
71. Miller, A. C.; Whittaker, T.; Thibault, A.; Samid, D. Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate. Int. J. Radiat. Biol., 1997, 72, 211-218.
72. Karagiannis, T. C.; Harikrishnan, K. N.; El-Osta, A. The histone deacetylase inhibitor, Trichostatin A, enhances radiation sensitivity and accumulation of gammaH2A.X. Cancer Biol. Ther., 2005, 4, 787-793.
73. Sonnemann, J.; Kumar, K. S.; Heesch, S.; Muller, C.; Hartwig, C.; Maass, M.; Bader, P.; Beck, J. F. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int. J. Oncol., 2006, 28, 755-766.
74. Munshi, A.; Tanaka, T.; Hobbs, M. L.; Tucker, S. L.; Richon, V. M.; Meyn, R. E. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol. Cancer Ther., 2006, 5, 1967-1974.
75. Seo, S. K.; Jin, H. O.; Lee, H. C.; Woo, S. H.; Kim, E. S.; Yoo, D. H.; Lee, S. J.; An, S.; Rhee, C. H.; Hong, S. I.; Choe, T. B.; Park, I. C. Combined effects of sulindac and suberoylanilide hydroxamic Acid on apoptosis induction in human lung cancer cells. Mol. Pharmacol., 2008, 73, 1005-1012.
76. Geng, L.; Cuneo, K. C.; Fu, A.; Tu, T.; Atadja, P. W.; Hallahan, D. E. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res., 2006, 66, 11298-11304.
77. Cuneo, K. C.; Fu, A.; Osusky, K.; Huamani, J.; Hallahan, D. E.; Geng, L. Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation. Anticancer Drugs, 2007, 18, 793-800.
78. Zaskodova, D.; Rezacova, M.; Vavrova, J.; Vokurkova, D.; Tichy, A. Effect of valproic acid, a histone deacetylase inhibitor, on cell death and molecular changes caused by low-dose irradiation. Ann. N. Y. Acad. Sci., 2006, 1091, 385-398.
79. Entin-Meer, M.; Rephaeli, A.; Yang, X.; Nudelman, A.; Vanden-Berg, S. R.; Haas-Kogan, D. A. Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas. Mol. Cancer Ther., 2005, 4, 1952-1961.
80. Entin-Meer, M.; Rephaeli, A.; Yang, X.; Nudelman, A.; Nudelman, A.; Haas-Kogan, D. A. AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. Cancer Lett., 2007, 253, 205-214.
81. Zhang, Y.; Adachi, M.; Zhao, X.; Kawamura, R.; Imai, K. Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl- methoxycarbonyl)amino-methyl]benzamide and mcarboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int. J. Cancer, 2004, 110, 301-308.
82. Sah, N. K.; Munshi, A.; Hobbs, M.; Carter, B. Z.; Andreeff, M.; Meyn, R. E. Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells. Int. J. Radiat. Oncol. Biol. Phys., 2006, 66, 852-859.
83. Zhang, Y.; Adachi, M.; Kawamura, R.; Zou, H. C.; Imai, K.; Hareyama, M.; Shinomura, Y. Bmf contributes to histone deacetylase inhibitor-mediated enhancing effects on apoptosis after ionizing radiation. Apoptosis, 2006, 11, 1349-1357.
84. Banuelos, C. A.; Banath, J. P.; MacPhail, S. H.; Zhao, J.; Reitsema, T.; Olive, P. L. Radiosensitization by the histone deacetylase inhibitor PCI-24781. Clin. Cancer Res., 2007, 13, 6816-6826.
85. Zhang, Y.; Adachi, M.; Zou, H.; Hareyama, M.; Imai, K.; Shinomura, Y. Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys., 2006, 65, 859-866.
86. Camphausen, K.; Burgan, W.; Cerra, M.; Oswald, K. A.; Trepel, J. B.; Lee, M. J.; Tofilon, P. J. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res., 2004, 64, 316-321.
87. Camphausen, K.; Cerna, D.; Scott, T.; Sproull, M.; Burgan, W. E.; Cerra, M. A.; Fine, H.; Tofilon, P. J. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int. J. Cancer, 2005, 114, 380-386.
88. Lopez, C. A.; Feng, F. Y.; Herman, J. M.; Nyati, M. K.; Lawrence, T. S.; Ljungman, M. Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys., 2007, 69, 214-220.
89. Kim, J. H.; Shin, J. H.; Kim, I. H. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int. J. Radiat. Oncol. Biol. Phys., 2004, 59, 1174-1180.
90. Zhang, Y.; Jung, M.; Dritschilo, A.; Jung, M. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat. Res., 2004, 161, 667-674.
91. Cerna, D.; Camphausen, K.; Tofilon, P. J. Histone deacetylation as a target for radiosensitization. Curr. Top Dev. Biol., 2006, 73, 173-204.
92. Chung, Y. L.; Wang, A. J.; Yao, L. F. Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy. Mol. Cancer Ther., 2004, 3, 317-325.
93. Paoluzzi, L.; Figg, W. D. Histone deacetylase inhibitors are potent radiation protectants. Cancer Biol. Ther., 2004, 3, 612-613.
94. Glasspool, R. M.; Teodoridis, J. M.; Brown, R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br. J. Cancer, 2006, 94, 1087-1092.
95. Karagiannis, T. C.; Smith, A. J.; El', O. A. Radio- and chemosensitization of human erythroleukemic K562 cells by the histone deacetylase inhibitor Trichostatin A. Hell. J. Nucl. Med., 2004, 7, 184-191.
96. Karagiannis, T. C.; Harikrishnan, K. N.; El-Osta, A. Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments. Oncogene, 2007, 26, 3963-3971.
97. Nome, R. V.; Bratland, A.; Harman, G.; Fodstad, O.; Andersson, Y.; Ree, A. H. Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death. Mol. Cancer Ther., 2005, 4, 1231-1238.
98. Bai, J.; Demirjian, A.; Sui, J.; Marasco, W.; Callery, M. P. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem. Biophys. Res. Commun., 2006, 348, 1245-1253.
99. Karagiannis, T. C.; Kn, H.; El-Osta, A. The epigenetic modifier, valproic acid, enhances radiation sensitivity. Epigenetics, 2006, 1, 131-137.
100. Hallows, K. R.; Bliven, S. F.; Leith, J. T. Effects of the differentiating agents sodium butyrate and N-methylformamide on the oxygen enhancement ratio of human colon tumor cells. Radiat. Res., 1988, 113, 191-198.
101. Adhikari, D.; Feroz, F.; Liefshitz, A.; Barakat, R. R.; Bertino, J. R.; Banerjee, D. Pretreatment of endometrial carcinoma cell lines with butyrate results in upregulation of Bax and correlates with potentiation of radiation induced cell kill. In Vivo, 2000, 14, 603-609.
102. Chung, Y. L.; Lee, Y. H.; Yen, S. H.; Chi, K. H. A novel approach for nasopharyngeal carcinoma treatment uses phenylbutyrate as a protein kinase C modulator: implications for radiosensitization and EBV-targeted therapy. Clin. Cancer Res., 2000, 6, 1452-1458.
103. Ferrandina, G.; Filippini, P.; Ferlini, C.; Maggiano, N.; Stoler, A. B.; Fruscella, E.; Mozzetti, S.; Mancuso, S.; Freedman, R. S.; Scambia, G.; Ranelletti, F. O. Growth inhibitory effects and radiosensitization induced by fatty aromatic acids on human cervical cancer cells. Oncol. Res., 2000, 12, 429-440.
104. Camphausen, K.; Scott, T.; Sproull, M.; Tofilon, P. J. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin. Cancer Res., 2004, 10, 6066-6071.